research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-15. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
== Cyclic Tetrapeptides == Cyclic tetrapeptides are a class of drugs that contain an α-epoxyketone group that has the potential to alkylate the HDAC active site. The HDAC active site, also known as histone deacetylase, are isozymes that modulate numerous regulatory signals and pathways within biological systems. They serve as targets for drug design. If the cyclic tetrapeptides were to alkylate the HDAC active site, they would deactivate the HDAC catalytic pocket. The tetra-peptide tuftsin (Thr–Lys–Pro–Arg), has been reported to affect a wide variety of biological responses in neutrophils and mononuclear phagocytes and also phagocytosis. It has also been reported that a tetra-peptide with the amino acid sequence, RGDS, that is from the cell-binding domain of the fibronectin molecule, is capable of blocking fibronectin from attaching to the cells. Based on that report, they were able to suggest that the RGDS tetra-peptide is capable of blocking RPE attachment to a variety of extracellular matrix component including; fibronectin, type I collagen, type II collagen, laminin, and lens capsule basement membrane. By utilizing time-lapse cinematography, it has been shown that the RGDS tetra-peptide inhibits the ability of cells to contract collagen.
=== Kyrgyzstan === Kyrgyzstan has a similar HIV/AIDS problem as Ukraine and to try and combat this, started a trial methadone program within prisons. The first program started in a solo prison is 2002 and expanded to multiple in 2008. It is estimated that half of incarcerated individuals in Kyrgyzstan inject drugs and the use of unsterilized needles and transfer of HIV is higher in the prison setting. While the offering of methadone in prisons would help curb the spread of HIV/AIDS, the internal prison governance of inmates and their reliance on the drug trade is a hard barrier. Heroin being used as currency as well as methadone users being assigned to separate living quarters than non-users creates a social separation between users and non-users. These outcasting factors can make methadone treatment not worth it for some inmates. The number of eligible prisoners using methadone through a methadone program is estimated at only 7%.
Hence, although DOM-NBOMe could still be an active psychedelic in humans, it may have attenuated hallucinogenic effects compared to non-25-NB DOx psychedelics. The doses of DOM-NBOMe producing the head-twitch response were not reported.
== Regulatory scrutiny == The Royal Australian College of General Practitioners (RACGP) raised concerns in 2023 about telehealth services using remote questionnaires to prescribe GLP-1 receptor agonists, questioning whether such methods provided adequate clinical assessment. The Therapeutic Goods Administration (TGA) warned telehealth companies against advertising prescription-only medicines directly to consumers. During GLP-1 medication shortages in 2023–2024, Eucalyptus partnered with compounding pharmacies to provide compounded semaglutide. This practice drew criticism from pharmaceutical manufacturers and regulators. The Australian federal government subsequently banned pharmacy compounding of GLP-1 drugs from October 2024. Media reports in The Sydney Morning Herald and The Australian questioned whether social media and influencer campaigns for Eucalyptus brands overstated treatment results. ABC's Media Watch raised concerns about whether television segments promoting the company's services blurred editorial and advertising boundaries. In response to regulatory concerns, Eucalyptus introduced phone-based GP consultations to replace asynchronous online forms. In June 2025, the TGA issued class-wide safety warnings for all GLP-1 and dual GIP/GLP-1 receptor agonists, including medications prescribed through Juniper, regarding aspiration risks during general anaesthesia. The warnings required updates to product information across all suppliers of these medications.
=== Need for stoichiometric control === There are two important aspects with regard to the control of molecular weight in polymerization. In the synthesis of polymers, one is usually interested in obtaining a product of very specific molecular weight, since the properties of the polymer will usually be highly dependent on molecular weight. Molecular weights higher or lower than the desired weight are equally undesirable. Since the degree of polymerization is a function of reaction time, the desired molecular weight can be obtained by quenching the reaction at the appropriate time. However, the polymer obtained in this manner is unstable, in that it leads to changes in molecular weight because the ends of the polymer molecule contain functional groups that can react further with each other. This situation is avoided by adjusting the concentrations of the two monomers so that they are slightly nonstoichiometric. One of the reactants is present in slight excess. The polymerization then proceeds to a point at which one reactant is completely used up and all the chain ends possess the same functional group of the group that is in excess. Further polymerization is not possible, and the polymer is stable to subsequent molecular-weight changes. Another method of achieving the desired molecular weight is by addition of a small amount of monofunctional monomer, a monomer with only one functional group.
Sources: en.wikipedia.org
Christopher Longuet-Higgins (1923–2004), British chemist with many contributions to theoretical chemistry Janis Louie, (born 1971), American chemist who works of catalisis by nickel-based systems Martin Lowry (1874–1936), British physical chemist who developed acid–base theory Sima Lozanić (1847–1935), Serbian chemist known for chemistry textbooks Alfred Lucas (1867–1945), Egypt-based English analytical chemist and archaeologist known for work after the excavation of Tutankhamun's tomb Ignacy Łukasiewicz (1802–1882), Polish pharmacist, inventor of the modern kerosene lamp
The outermost layer of the gastrointestinal wall consists of several layers of connective tissue and is either of serosa (below the diaphragm) or adventitia above the diaphragm. Regions of the gastrointestinal tract within the peritoneum (called Intraperitoneal) are covered with serosa. This structure consists of connective tissue covered by a simple squamous epithelium, called the mesothelium, which reduces frictional forces during digestive movements. The intraperitoneal regions include most of the stomach, first part of the duodenum, all of the small intestine, caecum and appendix, transverse colon, sigmoid colon and rectum. In these sections of the gut there is clear boundary between the gut and the surrounding tissue. These parts of the tract have a mesentery. Regions of the gastrointestinal tract behind the peritoneum (called retroperitoneal) are covered with adventitia. They blend into the surrounding tissue and are fixed in position (for example, the retroperitoneal section of the duodenum usually passes through the transpyloric plane). The retroperitoneal regions include the oral cavity, esophagus, pylorus of the stomach, distal duodenum, ascending colon, descending colon and anal canal.
Loss of consciousness can occur in myocardial infarctions due to inadequate blood flow to the brain and cardiogenic shock, and sudden death, frequently due to the development of ventricular fibrillation. When the brain was without oxygen for too long due to a myocardial infarction, coma and persistent vegetative state can occur. Cardiac arrest, and atypical symptoms such as palpitations, occur more frequently in females, the elderly, those with diabetes, in people who have just had surgery, and in critically ill patients.
=== Pharmacodynamics === DOPR acts as an agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It has very weak affinity for the serotonin 5-HT1 receptor. The drug has also been assessed at other receptors. It produces the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents. It is slightly more potent but slightly less efficacious than DOM in producing the head-twitch response. As with many other psychedelics, DOPR shows an inverted U-shaped dose–response curve in terms of the HTR, increasing it at lower doses and having diminished effectiveness at higher doses. DOPR showed no significant effects on locomotor activity in rodents at the assessed doses, but showed a trend towards hyperlocomotion at the highest dose. In a subsequent study however, it produced hyperlocomotion at lower doses and hypolocomotion at higher doses. The drug has shown pro-motivational effects in rodents at sub-hallucinogenic doses or so-called "microdoses". DOPR's close analogue DOET has also been clinically studied at sub-hallucinogenic doses as a "psychic energizer". DOPR produces antidepressant-like effects in rodents. At higher doses, DOPR produces hypothermia in rodents.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.